Young K, et al. - A retrospective cohort analysis was conducted to study the risk of venous thromboembolism (VTE) and its prognostic significance for patients treated with chemotherapy (chemo) and the EGFR monoclonal antibody necitumumab (neci) for metastatic non-small cell lung cancer (NSCLC). For overall survival (OS) analyses, a Cox proportional hazards model with VTE as a time-dependent covariate was used. Results of this study suggested that certain patient characteristics such as prior history of VTE and non-squamous histology could be associated with an increased risk of on-treatment VTE in NSCLC, despite the fact that in this investigation, overall survival was not affected.